Paul Baas
Bijzonder Hoogleraar Thoracale Oncologie, in het bijzonder Immunotherapie
- Naam
- Prof.dr. P. Baas
- Telefoon
- +31 20 5 121690
- p.baas@nki.nl
- ORCID iD
- 0000-0001-7018-9556
Buitengewoon Hoogleraar Thoracale Oncologie; in het bijzonder immuun therapie. Heine H Hansen life time award 2023. Ridder in de Orde van de Nederlandse Leeuw voor activiteiten voor asbestslachtoffers 2019.
Meer informatie over Paul Baas
Buitengewoon Hoogleraar Thoracale Oncologie; in het bijzonder immuun therapie. Heine H Hansen life time award 2023. Ridder in de Orde van de Nederlandse Leeuw voor activiteiten voor asbestslachtoffers 2019.
Longkanker
Het begeleiden van promovendi deels aangesteld in het Nederlands Kanker Instituut. Initiëren en uitvoeren van immuno studies in patiënten met longkanker. Nieuwe medicatie ontwikkeling met Prof JJC Neefjes.
Wetenschappelijke carrière
- Artsen diploma (UvA) 1986
- Longarts registratie (VUmc) 1990
- PhD: PDT in Mice and Men (UvA) 1994
- Hoogleraar (UvA) 2011
- Hoogleraar (LUMC) 2018
Bijzonder Hoogleraar Thoracale Oncologie, in het bijzonder Immunotherapie
- Faculteit Geneeskunde
- Divisie 4
- Klinische Oncologie
- Blomberg, O.S.; Spagnuolo, L.; Garner, H.; Voorwerk, L.; Isaeva, O.I.; Dyk, E. van; Bakker, N.; Chalabi, M.; Klaver, C.; Duijst, M.; Kersten, K.; Brüggemann, M.; Pastoors, D.; Hau, C.S.; Vrijland, K.; Raeven, E.A.M.; Kaldenbach, D.; Kos, K.; Afonina, I.S.; Kaptein, P.; Hoes, L.; Theelen, W.S.M.E.; Baas, P.; Voest, E.E.; Beyaert, R.; Thommen, D.S.; Wessels, L.F.A.; Visser, K.E. de & Kok, M. (2023), IL-5-producing CD4+ T cells and eosinophils cooperate to enhance response to immune checkpoint blockade in breast cancer, Cancer Cell 41(1): 106-+.
- Cuppens, K. & Baas, P. (2023), The path forward in early-stage lung cancer, Translational Lung Cancer Research 12(1): 11-13.
- Carbone, M.; Pass, H.I.; Ak, G.; Alexander, H.R.; Baas, P.; Baumann, F.; Blakely, A.M.; Bueno, R.; Bzura, A.; Cardillo, G.; Churpek, J.E.; Dianzani, I.; Rienzo, A. de; Emi, M.; Emri, S.; Felley-Bosco, E.; Fennell, D.A.; Flores, R.M.; Grosso, F.; Hayward, N.K.; Hesdorffer, M.; Hoang, C.D.; Johansson, P.A.; Kindler, H.L.; Kittaneh, M.; Krausz, T.; Mansfield, A.; Metintas, M.; Minaai, M.; Mutti, L.; Nielsen, M.; O'Byrne, K.; Opitz, I.; Pastorino, S.; Pentimalli, F.; Perrot, M. de; Pritchard, A.; Ripley, R.T.; Robinson, B.; Rusch, V.; Taioli, E.; Takinishi, Y.; Tanji, M.; Tsao, A.S.; Tuncer, A.M.; Walpole, S.; Wolf, A.; Yang, H.N.; Yoshikawa, Y.; Zolondick, A.; Schrump, D.S. & Hassan, R. (2022), Medical and Surgical Care of Patients With Mesothelioma and Their Relatives Carrying Germline BAP1 Mutations, Journal of Thoracic Oncology 17(7): 873-889.
- Scherpereel, A.; Antonia, S.; Bautista, Y.; Grossi, F.; Kowalski, D.; Zalcman, G.; Nowak, A.K.; Fujimoto, N.; Peters, S.; Tsao, A.S.; Mansfield, A.S.; Popat, S.; Sun, X.W.; Lawrance, R.; Zhang, X.Q.; Daumont, M.J.; Bennett, B.; McKenna, M. & Baas, P. (2022), First-line nivolumab plus ipilimumab versus chemotherapy for the treatment of unresectable malignant pleural mesothelioma: patient-reported outcomes in CheckMate 743, Lung Cancer 167: 8-16.
- Baas, P. (2022), Nivolumab Plus Ipilimumab Should Be the Standard of Care for First-Line Unresectable Epithelioid Mesothelioma, Journal of Thoracic Oncology 17(1): 30-33.
- Popat, S.; Baas, P.; Faivre-Finn, C.; Girard, N.; Nicholson, A.G.; Nowak, A.K.; Opitz, I.; Scherpereel, A.; Reck, M. & ESMO Guidelines Committee (2022), Malignant pleural mesothelioma, Annals of Oncology 33(2): 129-142.
- Peters, S.; Scherpereel, A.; Cornelissen, R.; Oulkhouir, Y.; Greillier, L.; Kaplan, M.A.; Talbot, T.; Monnet, I.; Hiret, S.; Baas, P.; Nowak, A.K.; Fujimoto, N.; Tsao, A.S.; Mansfield, A.S.; Popat, S.; Zhang, X.; Hu, N.; Balli, D.; Spires, T. & Zalcman, G. (2022), First-line nivolumab plus ipilimumab versus chemotherapy in patients with unresectable malignant pleural mesothelioma , Annals of Oncology 33(5): 488-499.
- Disselhorst, M.J.; Lubeck, Y.; Noort, V. van der; Quispel-Janssen, J.; Seignette, I.M.; Sanders, J.; Peters, D.; Hooijberg, E. & Baas, P. (2022), Immune cells in mesothelioma microenvironment simplistic marker of response to nivolumab plus ipilimumab?, Lung Cancer 173: 49-52.
- Kooten, J.P. van; Belderbos, R.A.; Thusen, J.H. von der; Aarts, M.J.; Verhoef, C.; Burgers, J.A.; Baas, P.; Aalbers, A.G.J.; Maat, A.P.W.M.; Aerts, J.G.J.V.; Cornelissen, R. & Madsen, E.V.E. (2022), Incidence, treatment and survival of malignant pleural and peritoneal mesothelioma, Thorax 77(12): 1260-1267.
- Boosman, R.J.; Gooijer, C.J. de; Groenland, S.L.; Burgers, J.A.; Baas, P.; Noort, V. van der; Beijnen, J.H.; Huitema, A.D.R. & Steeghs, N. (2022), Ritonavir-boosted exposure of kinase inhibitors, Pharmaceutical Research 39(4): 669-676.
- Ruschoff, J.H.; Haberecker, M.; Tsourti, Z.; Nackaerts, K.; Perrot, M. de; Brcic, L.; Nadal, E.; Tsimpoukis, S.; Gray, S.G.; Ampollini, L.; Aerts, J.G.; Felley-Bosco, E.; Kirschner, M.B.; Monkhorst, K.; Weynand, B.; Bavaghar-Zaeimi, F.; Samarzija, M.; Llatjos, R.; Finn, S.P.; Silini, E.; Thusen, J. von der; Marti, N.; Vervita, K.; Kammler, R.; Peters, S.; Stahel, R.A.; Baas, P.; Opitz, I. & ETOP Mesoscape Consortium (2022), Expression of phosphorylated ribosomal protein S6 in mesothelioma patients-correlation with clinico-pathological characteristics and outcome, Modern Pathology 35(12).
- Ruschoff, J.H.; Haberecker, M.; Tsourti, Z.; Nackaerts, K.; Perrot, M. de; Brcic, L.; Nadal, E.; Tsimpoukis, S.; Gray, S.G.; Ampollini, L.; Aerts, J.G.; Felley-Bosco, E.; Kirschner, M.B.; Monkhorst, K.; Weynand, B.; Bavaghar-Zaeimi, F.; Samarzija, M.; Llatjos, R.; Finn, S.P.; Silini, E.; Thusen, J. von der; Marti, N.; Vervita, K.; Kammler, R.; Peters, S.; Stahel, R.A.; Baas, P.; Opitz, I. & Consortium, E.M. (2022), Correction to: Expression of phosphorylated ribosomal protein S6 in mesothelioma patients-correlation with clinico-pathological characteristics and outcome, Modern Pathology 35(12).
- Kosari, F.; Disselhorst, M.; Yin, J.; Peikert, T.; Udell, J.; Johnson, S.; Smadbeck, J.; Murphy, S.; McCune, A.; Karagouga, G.; Desai, A.; Schaefer-Klein, J.; Borad, M.J.; Cheville, J.; Vasmatzis, G.; Baas, P. & Mansfield, A.S. (2022), Tumor junction burden and antigen presentation as predictors of survival in mesothelioma treated with immune checkpoint inhibitors, Journal of Thoracic Oncology 17(3): 446-454.
- Busacca, S.; O'Regan, L.; Singh, A.; Sharkey, A.J.; Dawson, A.G.; Dzialo, J.; Parsons, A.; Kumar, N.; Schunselaar, L.M.; Guppy, N.; Nakas, A.; Sheaff, M.; Mansfield, A.S.; Janes, S.M.; Baas, P.; Fry, A.M. & Fennell, D.A. (2021), BRCA1/MAD2L1 deficiency disrupts the spindle assembly checkpoint to confer vinorelbine resistance in mesothelioma, Molecular Cancer Therapeutics 20(2): 379-388.
- Buma, A.I.G.; Muller, M.; Vries, R. de; Sterk, P.J.; Noort, V. van der; Wolf-Lansdorf, M.; Farzan, N.; Baas, P. & Heuvel, M.M. van den (2021), eNose analysis for early immunotherapy response monitoring in non-small cell lung cancer, Lung Cancer 160: 36-43.
- Buma, A.I.G.; Muller, M.; Vries, R. de; Sterk, P.J.; Noort, V. van der; Wolf-Lansdorf, M.; Farzan, N.; Baas, P. & Heuvel, M.M. van den (2021), eNose analysis for early immunotherapy response monitoring in non-small cell lung cancer (vol 160, pg 36, 2021), Lung Cancer 162: 211-211.
- Peters, S.; Scherpereel, A.; Cornelissen, R.; Oulkhouir, Y.; Greillier, L.; Kaplan, M.A.; Talbot, T.; Monnet, I.; Hiret, S.; Baas, P.; Nowak, A.K.; Fujimoto, N.; Tsao, A.S.; Mansfield, A.S.; Popat, S.; Zhang, X.; Hu, N.; Balli, D.; Sanzari, J. & Zalcman, G. (2021), First-line nivolumab (NIVO) plus ipilimumab (IPI) vs chemotherapy (chemo) in patients (pts) with unresectable malignant pleural mesothelioma (MPM): 3-year update from CheckMate 743, Annals of Oncology 32: S1341-S1342.
- Baas, P.; Scherpereel, A.; Nowak, A.K.; Fujimoto, N.; Peters, S.; Tsao, A.S.; Mansfield, A.S.; Popat, S.; Jahan, T.; Antonia, S.; Oulkhouir, Y.; Bautista, Y.; Cornelissen, R.; Greillier, L.; Grossi, F.; Kowalski, D.; Rodriguez-Cid, J.; Aanur, P.; Oukessou, A.; Baudelet, C. & Zalcman, G. (2021), First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma (CheckMate 743), The Lancet 397(10272): 375-386.
- Dammeijer, F.; Gooijer, C.J. de; Gulijk, M. van; Lukkes, M.; Klaase, L.; Lievense, L.A.; Waasdorp, C.; Jebbink, M.; Bootsma, G.P.; Stigt, J.A.; Biesma, B.; Kaijen-Lambers, M.E.H.; Mankor, J.; Vroman, H.; Cornelissen, R.; Baas, P.; Noort, V. van der; Burgers, J.A. & Aerts, J.G. (2021), Immune monitoring in mesothelioma patients identifies novel immune-modulatory functions of gemcitabine associating with clinical response, EBioMedicine 64.
- Baas, P.; Daumont, M.J.; Lacoin, L.; Penrod, J.R.; Carroll, R.; Venkatesan, S.; Ubhi, H.; Calleja, A. & Snee, M. (2021), Treatment patterns and outcomes for patients with malignant pleural mesothelioma in England in 2013-2017, Lung Cancer 162: 185-193.
- Herbst, R.S.; Garon, E.B.; Kim, D.W.; Cho, B.C.; Gervais, R.; Perez-Gracia, J.L.; Han, J.Y.; Majem, M.; Forster, M.D.; Monnet, I.; Novello, S.; Gubens, M.A.; Boyer, M.; Su, W.C.; Samkari, A.; Jensen, E.H.; Kobie, J.; Piperdi, B. & Baas, P. (2021), Five year survival update from KEYNOTE-010, Research in Social and Administrative Pharmacy 16(10): 1718-1732.
- Baas, P.; Scherpereel, A.; Nowak, A.K.; Oukessou, A. & Zalcman, G. (2021), Heterogeneity of treatment effects in malignant pleural mesothelioma reply.
- Gooijer, C.J. de; Noort, V. van der; Broek, D. van den; Baas, P. & Burgers, J.A. (2021), Prognostic value of CYFRA 21.1 in malignant mesothelioma: A brief report of the randomized phase II trial NVALT19.
- Gooijer, C.J. de; Borm, F.J.; Scherpereel, A. & Baas, P. (2020), Immunotherapy in malignant pleural mesothelioma, Frontiers in Oncology 10.
- Disselhorst, M.J. & Baas, P. (2020), Chemotherapy options versus "novel" therapies: how should we treat patients with malignant pleural mesothelioma, Translational Lung Cancer Research 9: S77-S85.
- Herbst, R.S.; Garon, E.B.; Kim, D.W.; Cho, B.C.; Perez-Gracia, J.L.; Han, J.Y.; Arvis, C.D.; Majem, M.; Forster, M.D.; Monnet, I.; Novello, S.; Szalai, Z.; Gubens, M.A.; Su, W.C.; Ceresoli, G.L.; Samkari, A.; Jensen, E.H.; Lubiniecki, G.M. & Baas, P. (2020), Long-term outcomes and retreatment among patients with previously treated, programmed death-ligand 1-positive, advanced non-small-cell lung cancer in the KEYNOTE-010 study, Journal of Clinical Oncology 38(14): 1580-+.
- Thunnissen, E.; Kerr, K.M.; Dafni, U.; Bubendorf, L.; Finn, S.P.; Soltermann, A.; Biernat, W.; Cheney, R.; Verbeken, E.; Warth, A.; Marchetti, A.; Speel, E.J.M.; Pokharel, S.; Quinn, A.M.; Monkhorst, K.; Navarro, A.; Madsen, L.B.; Tsourti, Z.; Geiger, T.; Kammler, R.; Peters, S.; Stahel, R.A.; Stahel, R.A.; Rosell, R.; Blackhall, F.; Dafni, U.; Kerr, K.M.; Molina, M.A.; Bubendorf, L.; Weder, W.; Thunnissen, E.; Peters, S.; Finn, S.; Hiltbrunner, A.; Kammler, R.; Geiger, T.; Marti, N.; Tsourti, Z.; Polydoropoulou, V.; Zygoura, P.; Nicolson, M.; Stevenson, D.A.J.; Mathieson, W.; Smit, E.; Radonic, T.; Soltermann, A.; Rulle, U.; Curioni, A.; Gray, S.G.; Gately, K.; Barr, M.; Meldgaard, P.; Madsen, L.B.; Savic, S.; Lardinois, D.; Nackaerts, K.; Dooms, C.; Wauters, E.; Borght, S. van der; Biernat, W.; Wrona, A.; Rzyman, W.; Jassem, J.; Dienemann, H.; Muley, T.; Warth, A.; Marchetti, A.; Luca, G. de; Lorito, A. di; Dingemans, A.M.; Speel, E.J.M.; Ruland, A.; Pokharel, S.; Cheney, R.; Ferenczy, P.; Quinn, A.M.; Franklin, L.; Baas, P.; Monkhorst, K.; Wiel, B. van de; Camps, C.; Martorell, M.; Navarro, A. & European Thoracic Oncology (2020), Programmed death-ligand 1 expression influenced by tissue sample size. Scoring based on tissue microarrays' and cross-validation with resections, in patients with, stage I-III, non-small cell lung carcinoma of the European Thoracic Oncology Platform Lungscape cohort, Modern Pathology 33(5): 792-801.
- Nicholson, A.G.; Sauter, J.L.; Nowak, A.K.; Kindler, H.L.; Gill, R.R.; Remy-Jardin, M.; Armato, S.G.; Fernandez-Cuesta, L.; Bueno, R.; Alcala, N.; Foll, M.; Pass, H.; Attanoos, R.; Baas, P.; Beasley, M.B.; Brcic, L.; Butnor, K.J.; Chirieac, L.R.; Churg, A.; Courtiol, P.; Dacic, S.; Perrot, M. de; Frauenfelder, T.; Gibbs, A.; Hirsch, F.R.; Hiroshima, K.; Husain, A.; Klebe, S.; Lantuejoul, S.; Moreira, A.; Opitz, I.; Perol, M.; Roden, A.; Roggli, V.; Scherpereel, A.; Tirode, F.; Tazelaar, H.; Travis, W.D.; Tsao, M.S.; Schil, P. van; Vignaud, J.M.; Weynand, B.; Lang-Lazdunski, L.; Cree, I.; Rusch, V.W.; Girard, N. & Galateau-Salle, F. (2020), EURACAN/IASLC proposals for updating the histologic classification of pleural mesothelioma, Journal of Thoracic Oncology 15(1): 29-49.
- Zazuli, Z.; Kos, R.; Veltman, J.D.; Uyterlinde, W.; Longo, C.; Baas, P.; Masereeuw, R.; Vijverberg, S.J.H. & Zee, A.H.M. van der (2020), Comparison of myelotoxicity and nephrotoxicity between daily low-dose cisplatin with concurrent radiation and cyclic high-dose cisplatin in non-small cell lung cancer patients, Frontiers in Pharmacology 11.
- Mankor, J.M.; Disselhorst, M.J.; Poncin, M.; Baas, P.; Aerts, J.G.J.V. & Vroman, H. (2020), Efficacy of nivolumab and ipilimumab in patients with malignant pleural mesothelioma is related to a subtype of effector memory cytotoxic T cells, EBioMedicine 62.
- Cantini, L.; Belderbos, R.A.; Gooijer, C.J.; Dumoulin, D.W.; Cornelissen, R.; Baart, S.; Burgers, J.A.; Baas, P. & Aerts, J.G.J.V. (2020), Nivolumab in pre-treated malignant pleural mesothelioma, Translational Lung Cancer Research 9(4): 1169-+.
- Schouten, R.D.; Egberink, L.; Muller, M.; Gooijer, C.J. de; Werkhoven, E. van; Heuvel, M.M. van den & Baas, P. (2020), Nivolumab in pre-treated advanced non-small cell lung cancer, Translational Lung Cancer Research 9(5): 1736-+.
- Zandwijk, N. van; Reid, G. & Baas, P. (2020), Editorial: emerging therapies for malignant mesothelioma, Frontiers in Oncology 10.
- Theelen, W.S.M.E.; Jong, M.C. de & Baas, P. (2020), Synergizing systemic responses by combining immunotherapy with radiotherapy in metastatic non-small cell lung cancer: The potential of the abscopal effect, Lung Cancer 142: 106-113.
- Theelen, W.S.M.E.; Chen, D.W.; Verma, V.; Hobbs, B.P.; Peulen, H.M.U.; Aerts, J.G.J.V.; Bahce, I.; Niemeijer, A.L.N.; Chang, J.Y.; Groot, P.M. de; Nguyen, Q.N.; Comeaux, N.I.; Simon, G.R.; Skoulidis, F.; Lin, S.H.; He, K.W.; Patel, R.; Heymach, J.; Baas, P. & Welsh, J.W. (2020), Pembrolizumab with or without radiotherapy for metastatic non-small-cell lung cancer: a pooled analysis of two randomised trials, The Lancet Respiratory Medicine 9(5): 467-475.
- Paul Baas (2018), ESMO handbook of immuno-oncology Chapter Mesothelioma.
- Gooijer, C.J. de; Baas, P. & Burgers, J.A. (2018), Current chemotherapy strategies in malignant pleural mesothelioma, Translational lung cancer research 7(5): 574-583.
- Buikhuisen, W.A.; Hiddingab, B.I.; Baas, P. & Meerbeeck, J.P. van (2015), Second line therapy in malignant pleural mesothelioma: A systematic review, Lung Cancer 89(3): 223-231.